Transforming inline viscometer into a PAT tool for measuring real-time protein concentration in TFF operation

20th of June 2024, Boston

Zsofia Bencze Downstream Process Development Scientist

Building families and helping people live better lives



Company overview



Privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives



Leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology



At the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy



Ferring has a full spectrum of products from conception to birth



Founded in Malmö, Sweden in 1950, headquartered in Switzerland



Global company with over 7,000 employees in more than 50 countries, and distribution in over 100 countries




2023 revenue: EUR 2.2 billion* 2023 R&D investment: 16%


*USD 2.3 billion - CHF 2.1 billion




Ferring Biologics Innovation Centre (FBIC)












Drug Substance CMC Development, from microliters to 200-liters scale.



Why implementing Process Analytical Technologies (PATs) in a TFF setup is the go-to approach?

Give back time to the scientists!



Understand our process



Predict (impact of buffer systems, fluid temperature, concentration, ...etc.)



Speed-up process design and optimisation



Reduce experimental cost



Secure scale-up

First real-time protein concentration monitoring at FBIC with *Levitronix* inline viscometer



Tangential Flow Filtration (TFF)

A unit operation, that is often performed manually in the industry even at manufacturing scale.

mAb – IgG1

A straightforward, robust molecule to work with.

Cali time

Expected outcome

Calibration and integration of inline viscometer for realtime protein concentration estimation, shorter processing time, lower cost of goods and less resources.



Stages of implementation



Outline the Project

- Automated monitoring and control.
- Integrated feedback loops based on PAT
- Increased robustness and accuracy, supplementing balance readout with viscosity.
- Scalable, transferable, single use, and affordable solution, made from certified material.



Laboratory

- Process design for an IgG1 molecule.
- Two different formulation recipes.
- Calibration of the inline viscometer for each buffer system.
- High concentration UF/DF/UF runs with each buffer systems.
- Upgraded TFF system with Levitronix PATs (inline viscometer) and consols.
- Automated TMP control for less manual interaction.




Model Building

- Prediction model building based on calibration experiments.
- Viscosity data can be transformed to concentration data.
- Reference concentration and viscosity measurement to confirm inline and atline data. (Solo VPE for A280, microVISC for viscosity).



Time investment overview by stages



Description of experiments

Inline Viscosimeter Calibration Experiments


- 10 datapoints
- Start concentration: 140 mg/mL. End concentration 5 mg/mL.
- Temperature ramping from 20-28 °C for each datapoint
- Calibration of viscometer PAT tool with two commercial formulation recipes for IgG1.

High Concentration Tangential Flow Filtration


- Two different formulation buffer recipe tested
- 5 g of IgG1 material was loaded on 0.02 m² membrane.
- UF1: 5 to 50 mg/mL.
- Diafiltration: 7 DVs, controlled by flowmeter, balances, conductivity and inline viscometer PAT.
- UF2: up to 140 mg/mL.



Calibration setup for prediction model building




Calibration results of data analyses



System setup


10




concentration values, instead of gravimetrically defined method phase changes (less precise, output of balances on feed and permeate sides).



Start 1st Ultrafiltration







Start Concentration (mg/mL)	
Start Volume (mL)	

Transmembrane Pressure (bar)

5	Online viscosity	Viscometer PAT	Levitronix	continuous data red	cording	
1000	Offline viscosity	microVISC	Rheosense	reference		
	Offline validated concentration	Solo VPE	C-Technologies, Repligen	reference		
	Offline concentration for monitoring	Nanophotometer	Implen	confirming volume introducing phase of	Ŷ	
1.2	SEC-HPLC	Vanquish Flex	Thermo Scientific	quality information	FERRING	
					PHARMACEUTICALS	

Finish 1st Ultrafiltration and start Diafiltration





End Concentration (mg/mL)	50
End Volume (mL)	100
Duration (min)	105
Transmembrane Pressure (bar)	1.2

Online viscosity	Viscometer PAT	Levitronix	continuous data recording
Offline viscosity	microVISC	Rheosense	reference
Offline validated concentration	Solo VPE	C-Technologies, Repligen	reference
Offline concentration for monitoring	Nanophotometer	Implen	confirming volume changes and introducing phase change
SEC-HPLC	Vanquish Flex	Thermo Scientific	quality information FERRING
			PHARMACEUTICALS


During Diafiltration




Start Concentration (mg/mL)	50
Start Volume (mL)	100
End Concentration (mg/mL)	50
End Volume (mL)	100
Diafiltration Volumes	7
Duration (min)	80
Transmembrane Pressure (bar)	1.2

Online viscosity	Viscometer PAT	Levitronix	continuous data recording
Offline viscosity	microVISC	Rheosense	reference
Offline validated concentration	Solo VPE	C-Technologies, Repligen	reference
Offline concentration for monitoring	Nanophotometer	Implen	confirming volume changes and introducing phase change
SEC-HPLC	Vanquish Flex	Thermo Scientific	quality information FERRING
			PHARMACEUTICALS

Finish Diafiltration and start 2nd Ultrafiltration






Start Concentration (mg/mL)	
Start Volume (mL)	


Transmembrane Pressure (bar)

50	Online viscosity	Viscometer PAT	Levitronix	continuous data re	cording
100	Offline viscosity	microVISC	Rheosense	reference	
	Offline validated concentration	Solo VPE	C-Technologies, Repligen	reference	
	Offline concentration for monitoring	Nanophotometer	Implen	confirming volume	•
1.2	SEC-HPLC	Vanquish Flex	Thermo Scientific	quality information	FERRING
					PHARMACEUTICALS

PHARMACEUTICALS

Finish 2nd Ultrafiltration






End Concentration (mg/mL)	140
End Volume (mL)	36
Duration (min)	25
Transmembrane Pressure (bar)	1.2

Online viscosity	Viscometer PAT	Levitronix	continuous data recording
Offline viscosity	microVISC	Rheosense	reference
Offline validated concentration	Solo VPE	C-Technologies, Repligen	reference
Offline concentration for monitoring	Nanophotometer	Implen	confirming volume changes and introducing phase change
SEC-HPLC	Vanquish Flex	Thermo Scientific	quality information FERRING
			PHARMACEUTICALS


Monomer content of each sample during the process remained >96%, quality was not compromised.

Validation of calibration



• Four samples were taken during the TFF process to measure reference concentration value on Solo VPE, as a form of validation of the built prediction model.

- Good alignment between reference concentration and transformed viscosity data.
- The dashed lines are representing ±5% range from the setpoints in the process.





[g/L]

4.4

52.6

51.0

135.4

Outlook and Applicability



17

Better control





Automated



Reliable results



Mechanistic, hybrid, or statistical modelling



Process knowledge



Opportunities to compare conditions



Less human interaction with the system setup





Acknowledgments

Ferring

FBIC team (Jessikah Swasbrook, Analytical Scientist)

PDDD formulation team

Levitronix

Antony Sibilia (Business Development Manager)

Patrick Romann (Bioprocess Specialist)



Thank you!

